

PSJ3

Exhibit 172

FINAL MINUTES

Industry Working Group (IWG) – Face-to-Face Kick-Off Meeting

Tuesday, April 7, 2009

TOPIC	SUMMARY/DECISIONS	ACTIONS
Legal Statement <ul style="list-style-type: none"> Antitrust compliance statement and guidelines 	<ul style="list-style-type: none"> Antitrust issue discussed by J. Dean, Covington & Burling There were no objections to proceeding with the meeting given this discussion 	<ul style="list-style-type: none"> N/A
Welcome Introductions	<ul style="list-style-type: none"> Introductions of all participants on the telephone and those in the meeting room. 	<ul style="list-style-type: none"> N/A
Identify Meeting Goals <ul style="list-style-type: none"> Define operating principles of the Working Group Agree on key issues to be addressed/evaluated by the Working Group Determine next steps 	<ul style="list-style-type: none"> There was agreement with the meeting goals No additional meeting goals were identified 	<ul style="list-style-type: none"> N/A
Operating Principles of Working Group <ul style="list-style-type: none"> Agree on primary member organizations/structure <ul style="list-style-type: none"> One collaborative Industry Working Group (IWG) or other options Key stakeholders Other Industry members not included in the FDA directive 	<ul style="list-style-type: none"> The group agreed to proceed with one IWG to address the FDA directive <ul style="list-style-type: none"> The meeting of ANDA holders scheduled for April 20th was discussed; it was agreed that this meeting would be held as an ANDA sub-team and the results reported back to the IWG It was agreed that the working group should only include the 26 companies identified by FDA as invitees to the March 3rd meeting Additional input from other industry and non-industry (e.g., vendors) interested parties as well as stakeholders will be elicited through appropriate sub-teams It was agreed that a Charter would be drafted by a sub-team and would include the following working principles: <ul style="list-style-type: none"> Agree to abide by the antitrust guidelines Agree that all members will have an equal voice Agree to strive for consensus for all decisions Agree that membership will include the 26 member companies as identified by FDA 	<ul style="list-style-type: none"> Sub-team to draft IWG charter and provide draft for discussion at next face-to-face meeting

4/8/09

Page 1 of 6

FINAL MINUTES

Industry Working Group (IWG) – Face-to-Face Kick-Off Meeting

Tuesday, April 7, 2009

TOPIC	SUMMARY/DECISIONS	ACTIONS
Pain Care Forum <ul style="list-style-type: none"> Pain Care Forum REMS Task Force Class Opioids REMS Recommendations to FDA 	<ul style="list-style-type: none"> W. Rowe provided an overview of the PCF REMS Task Force and highlighted the current draft of their recommendations document which is 75-80% complete (slides to be provided) It was noted by Covidien that, although the document is called a “consensus” document, there were several key areas in which there was not “substantial agreement” by all PCF members It was suggested by Covidien that the core document include only those areas where there was substantial agreement and the other differing opinions be included as an appendix W. Rowe stated that the following meetings were scheduled at FDA and there would be representation by various members of the PCF: <ul style="list-style-type: none"> April 29 – AMA, medical specialties May 4 – prescribers May 4 – benefit managers and insurance providers May 5 – pt. advocacy groups including PCF May 5 – dispensers (pharmacists) A 6th meeting will be requested by the PCF to discuss their recommendations which they plan to have complete by the third week in April It was agreed that the IWG should contact FDA about participating as an observer in these various meetings so that we can incorporate this stakeholder input into our REMS proposal 	<ul style="list-style-type: none"> Sub-team to contact FDA to discuss participation as an observer in various stakeholder meetings.

4/8/09

Page 2 of 6

FINAL MINUTES

Industry Working Group (IWG) – Face-to-Face Kick-Off Meeting

Tuesday, April 7, 2009

TOPIC	SUMMARY/DECISIONS	ACTIONS
Elements of a Class-Wide REMS <ul style="list-style-type: none"> Assess the directive given to Industry by FDA <ul style="list-style-type: none"> What additional information do we need? What additional issues does this Working Group need to address? Which elements can this Working Group address? Which elements are outside of the scope of this Working Group? Engagement of key stakeholders 	<ul style="list-style-type: none"> The following issues were identified as needing additional information/ vetting: <ul style="list-style-type: none"> How do we measure change to benefit? Regarding the requirement of experience, training and/or certification as specified in FDAAA, “what” experience, “what” training and “what” certification will be required? What elements do we, as Industry, have the ability to influence or control? What are the Objectives of the proposed REMS that will allow us to meet the FDA stated Goals? 	<ul style="list-style-type: none"> Three sub-teams were formed to begin discussing potential Elements to Assure Safe Use (prescribers, patients, dispensers) – see Appendix 1 for sub-team membership Engagement of key stakeholders will be determined by the sub-teams
Development of sub-teams <ul style="list-style-type: none"> Identification of sub-teams <ul style="list-style-type: none"> Roles Responsibilities Membership 	<ul style="list-style-type: none"> Initially the following sub-teams were identified: <ul style="list-style-type: none"> Elements to Assure Safe Use Regulatory (FDA Communication) Legal Finance Logistics/Administrative Policy (to evaluate issues outside of the REMS directive such as inclusion of IR products) Evaluation/Metrics ANDA Holders Stakeholders PR – messaging After further discussion, it was agreed that that the following sub-teams would be formed <i>at this time</i>: <ul style="list-style-type: none"> Operations Communications Elements to Assure Safe Use <ul style="list-style-type: none"> Prescribers Patients Dispensers 	<ul style="list-style-type: none"> Membership of sub-teams and point person outlined in Attachment 1 Provide TBD names to E. Smith by COB 4/8/2009 Sub-teams to convene by teleconference by April 10 to begin work and plan for agenda items for next face-to-face meeting Communication sub-team lead (E. Ernst) to contact FDA (B. Rappaport or S. Hertz) by phone to provide update on IWG An e-mail will also be drafted and circulated to the IWG for review prior to sending to FDA (E. Ernst)

4/8/09

Page 3 of 6

FINAL MINUTES

Industry Working Group (IWG) – Face-to-Face Kick-Off Meeting

Tuesday, April 7, 2009

TOPIC	SUMMARY/DECISIONS	ACTIONS
Next Steps <ul style="list-style-type: none">Plan for the next meeting of the Working GroupEstablishment of a Charter	<ul style="list-style-type: none">Next IWG teleconference will be held the week of April 13ANDA holder sub-team will meet on April 20 and Covidien will provide a report of this meeting to the IWG the week of April 27Next face-to-face meeting will be held the week of May 11 so that an update from the FDA stakeholder meetings can be discussedPurdue agreed to host next face-to-face meeting in MayDraft charter to be remit of Operations sub-team	<ul style="list-style-type: none">Sub-teams to convene TC by April 10Operations sub-team to schedule IWG TC for week of April 13th and the next face-to-face meeting for the week of May 11th
Wrap-up <ul style="list-style-type: none">Summary/next actions		<ul style="list-style-type: none">Minutes to be prepared and distributed by E. Smith
Adjourn		

FINAL MINUTES

Industry Working Group (IWG) – Face-to-Face Kick-Off Meeting

Tuesday, April 7, 2009

ATTACHMENT 1 – List of Sub-teams

Sub-team: Operations

Purpose: Coordinate logistics for meetings, draft IWG charter, investigate outside project management support, discuss need for budget

Membership: Craig Landau – Purdue (point person)
Jill Buckley – King
Kishore Gopu – Teva
Mylan (TBD)
J&J (TBD)

Sub-team: Communications

Purpose: Communicate with FDA regarding status of IWG and request participation in FDA-sponsored stakeholder meetings

Membership: Elizabeth Ernst – Roxane (point person)
Martin Lessem – Ranbaxy
Marsha Stanton – King
Michael Kaufman – J&J
Burt Rosen – Purdue
Tara Chapman – Endo
Arthur Ilse – Xanodyne
John Lay – Vista
Nick Tantillo – Teva/Barr
Andrea Miller – Mylan
Lorri Scheussler – Hisamitsu
Beth Brannan – Watson
Lesley Zhu – Sandoz

Sub-team: Elements to Assure Safe Use

Purpose: Gather information and evaluate potential Elements of Safe Use

Prescribers
Dave Haddox – Purdue (point person)
Eric Davis – Mylan
Mike Nelson – Neuromed
Sid Schnoll – Roxane
J&J – TBD
Shabana Modan – Ranbaxy
Eric Smith – King
Frank Yuen – Endo

Patients
Sid Schnoll – Roxane (point person)
Shabana Modan – Ranbaxy
J&J – TBD
Lori Scheussler – Hisamitsu
Deb Myers – Roxane

4/8/09

Page 5 of 6

Industry Working Group (IWG) – Face-to-Face Kick-Off Meeting

Tuesday, April 7, 2009

ATTACHMENT 1 – List of Sub-teams (cont'd)

Dispensers

point person – TBD

Tara Chapman – Endo

Kimberly France – Covidien

Gary Kosloski – Watson

Purdue - TBD

J&J – TBD

Mylan – TBD

Sandoz – TBD